In particular, MAGE-A3 and MAGE-A10 have been identified in non-small cell lung cancers (NSCLC), bladder cancers, esophageal and head and neck cancers, and sarcomas [34]. Here, MAGEA3 is linked to urinary bladder carcinoma.